ArticleVirus research2026
Epitope-based vaccine of NiV targeting glycoprotein and fusion protein: an integrated immunoinformatics and bioinformatics approach.
Article in Virus research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
NiV is an ongoing infection that causes severe complications, and its frequent outbreaks make its treatment more complicated in terms of the proper therapeutic design. No viable vaccine candidate exists to combat NiV; however, efforts are underway, and some vaccines are in clinical trials. Therefore, an integrated immunoinformatics and bioinformatics approach was employed to design a promising epitope-based vaccine targeting glycoprotein and fusion protein, which are critical for host-pathogen interactions. The two targets, i.e., glycoprotein and fusion protein, were examined to identify B- and T-cell epitopes. A total of 3 B cell, 13 MHC I and 7 MHC II epitopes from both targets were chosen for vaccine formulation. Epitopes were joined using specific linkers and combined with three different adjuvants to generate 3 vaccines, i.e., VC1, VC2, and VC3, enabling selection of the best construct based on antigenicity. PADRE and a 6 × His-tag were also included. Analysis resulted in VC2 as a highly immunodominant profile. The incorporated epitopes resulted in broad global population coverage ( 98.97%) and remarkable stereochemical properties of the modelled vaccine, as assessed via 2D and 3D analyses. Subsequently, the VC2 were docked to the toll-like receptors (TLR2, TLR3, and TLR4) and showed high binding affinities of -14.2 to -23.1kcal/mol, along with H-bonds (9 to 20). Among them, the VC2-TLR3 complex showed the most promising interaction and demonstrated stability based on the NMA analysis (eigenvalue = 1.710065e-06), followed by a 100-ns simulation and RMSD, RMSF, etc. Furthermore, the immune simulation and expression analysis revealed remarkable immune activity in a dose-dependent manner, yielding promising GC% and CAI values. Based on the integrated framework, the study demonstrated that the designed vaccine, incorporating variations in the adjuvant, may exhibit significant immunodominant activity and could help combat NiV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.